Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.52 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.52 |
| ▸ | TP53 | P04637 | 1/20 | 0.52 |
| ▸ | GSK3B | P49841 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 2/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | DAO | P14920 | 1/20 | 0.36 |
| ▸ | CES2 | O00748 | 1/20 | 0.34 |
| ▸ | CES1 | P23141 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 2/20 | 0.31 |
| ▸ | CLK1 | P49759 | 1/20 | 0.31 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.31 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | GLA | P06280 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL560732 | 0.81 | DAO (0.52) | MAPTDAOCES2CES1KDM4E | |
| SCHEMBL9974183 | 0.79 | CTPS1 (0.40) | MAPTNPSR1POLBHPGDDAO | |
| SCHEMBL23092955 | 0.74 | ALDH1A1 (0.37) | DAOALDH1A1 | |
| SCHEMBL361988 | 0.74 | ALDH1A1 (0.40) | MAPTGSK3BPOLBHPGDCA2 | |
| SCHEMBL1612962 | 0.71 | — | — | |
| SCHEMBL3450 | 0.71 | — | — | |
| SCHEMBL461797 | 0.71 | ALDH1A1 (0.36) | MAPTPOLBLMNAALDH1A1L3MBTL1 | |
| SCHEMBL1665488 | 0.70 | — | — | |
| SCHEMBL3248570 | 0.70 | — | — | |
| SCHEMBL21963324 | 0.70 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9303033-B2 | Pyrazolopyrimidines and related heterocycles as CK2 inhibitors | SENHWA BIOSCIENCES, INC. (TW) | 2016-04-05 | — | — | US | disclosed |
| US-8476300-B2 | Selective estrogen receptor modulator for the treatment of osteoarthritis | ELI LILLY AND COMPANY (US) | 2013-07-02 | — | — | US | disclosed |
| US-20110166182-A1 | Selective Estrogen Receptor Modulator for the Treatment of Osteoarthritis | ELI LILLY AND COMPANY (US) | 2011-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110166182-A1 | Selective Estrogen Receptor Modulator for the Treatment of Osteoarthritis | ESRRA, GPER1, ESR2 | MAPT 3514/4885NPSR1 156/4885TP53 881/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.